Literature DB >> 29977064

Anticoagulants impact on innate immune responses and bacterial survival in whole blood models of Neisseria meningitidis infection.

Lea Strobel1, Kay O Johswich2.   

Abstract

Neisseria meningitidis (meningococcus) causes invasive diseases such as meningitis or septicaemia. Ex vivo infection of human whole blood is a valuable tool to study meningococcal virulence factors and the host innate immune responses. In order to consider effects of cellular mediators, the coagulation cascade must be inhibited to avoid clotting. There is considerable variation in the anticoagulants used among studies of N. meningitidis whole blood infections, featuring citrate, heparin or derivatives of hirudin, a polypeptide from leech saliva. Here, we compare the influence of these three different anticoagulants, and additionally Mg/EGTA, on host innate immune responses as well as on viability of N. meningitidis strains isolated from healthy carriers and disease cases, reflecting different sequence types and capsule phenotypes. We found that the anticoagulants significantly impact on cellular responses and, strain-dependently, also on bacterial survival. Hirudin does not inhibit complement and is therefore superior over the other anticoagulants; indeed hirudin-plasma most closely reflects the characteristics of serum during N. meningitidis infection. We further demonstrate the impact of heparin on complement activation on N. meningitidis and its consequences on meningococcal survival in immune sera, which appears to be independent of the heparin binding antigens Opc and NHBA.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29977064      PMCID: PMC6033889          DOI: 10.1038/s41598-018-28583-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  58 in total

1.  Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis.

Authors:  Tom Sprong; Petter Brandtzaeg; Michael Fung; Anne M Pharo; E Arne Høiby; Terje E Michaelsen; Audun Aase; Jos W M van der Meer; Marcel van Deuren; Tom E Mollnes
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

2.  Disease and Carrier Isolates of Neisseria meningitidis Cause G1 Cell Cycle Arrest in Human Epithelial Cells.

Authors:  Michael von Papen; Wilhelm F Oosthuysen; Jérôme Becam; Heike Claus; Alexandra Schubert-Unkmeir
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

3.  The use of heparin in meningococcal disease.

Authors:  D Oberholzer; J P Lowe
Journal:  Proc Mine Med Off Assoc       Date:  1972 Jan-Apr

4.  C3 shunt activation in human serum chelated with EGTA.

Authors:  D P Fine; S R Marney; D G Colley; J S Sergent; R M Des Prez
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

5.  Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells.

Authors:  M Virji; K Makepeace; D J Ferguson; M Achtman; E R Moxon
Journal:  Mol Microbiol       Date:  1993-11       Impact factor: 3.501

6.  Analysis of the regulated transcriptome of Neisseria meningitidis in human blood using a tiling array.

Authors:  Elena Del Tordello; Silvia Bottini; Alessandro Muzzi; Davide Serruto
Journal:  J Bacteriol       Date:  2012-09-14       Impact factor: 3.490

7.  Identification of the immunoproteome of the meningococcus by cell surface immunoprecipitation and MS.

Authors:  Jane Newcombe; Tom A Mendum; Chuan-peng Ren; Johnjoe McFadden
Journal:  Microbiology       Date:  2013-11-25       Impact factor: 2.777

8.  Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood.

Authors:  Shan Huang; Kerstin Sandholm; Nina Jonsson; Anders Nilsson; Anders Wieslander; Gunilla Grundström; Viktoria Hancock; Kristina N Ekdahl
Journal:  Clin Kidney J       Date:  2014-12-01

9.  Transcriptomic buffering of cryptic genetic variation contributes to meningococcal virulence.

Authors:  Biju Joseph Ampattu; Laura Hagmann; Chunguang Liang; Marcus Dittrich; Andreas Schlüter; Jochen Blom; Elizaveta Krol; Alexander Goesmann; Anke Becker; Thomas Dandekar; Tobias Müller; Christoph Schoen
Journal:  BMC Genomics       Date:  2017-04-07       Impact factor: 3.969

Review 10.  Meningococcal disease and the complement system.

Authors:  Lisa A Lewis; Sanjay Ram
Journal:  Virulence       Date:  2013-10-08       Impact factor: 5.882

View more
  10 in total

1.  Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study.

Authors:  Erica Quaquarini; Federico Sottotetti; Francesco Agustoni; Emma Pozzi; Alberto Malovini; Cristina Maria Teragni; Raffaella Palumbo; Giuseppe Saltalamacchia; Barbara Tagliaferri; Emanuela Balletti; Pietro Rinaldi; Costanza Canino; Paolo Pedrazzoli; Antonio Bernardo
Journal:  J Pers Med       Date:  2022-04-24

2.  Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation.

Authors:  Nuzhat Maisha; Tobias Coombs; Erin Lavik
Journal:  ACS Biomater Sci Eng       Date:  2020-07-06

3.  Extracorporeal Membrane Oxygenation-Induced Hemolysis: An In Vitro Study to Appraise Causative Factors.

Authors:  Chris Hoi Houng Chan; Katrina K Ki; Meili Zhang; Cooper Asnicar; Hwajin Cho; Carmen Ainola; Mahe Bouquet; Silver Heinsar; Jo Philipp Pauls; Gianluigi Li Bassi; Jacky Suen; John F Fraser
Journal:  Membranes (Basel)       Date:  2021-04-25

4.  A homopolymeric adenosine tract in the promoter region of nspA influences factor H-mediated serum resistance in Neisseria meningitidis.

Authors:  Heike Claus; Kerstin Hubert; Dörte Becher; Andreas Otto; Marie-Christin Pawlik; Ines Lappann; Lea Strobel; Ulrich Vogel; Kay Johswich
Journal:  Sci Rep       Date:  2019-02-25       Impact factor: 4.379

5.  Ex vivo observation of granulocyte activity during thrombus formation.

Authors:  Daria S Morozova; Alexey A Martyanov; Sergei I Obydennyi; Julia-Jessica D Korobkin; Alexey V Sokolov; Ekaterina V Shamova; Irina V Gorudko; Anna L Khoreva; Anna Shcherbina; Mikhail A Panteleev; Anastasia N Sveshnikova
Journal:  BMC Biol       Date:  2022-02-07       Impact factor: 7.431

6.  Bacterial phagocytosis and reactive oxygen species production by camel neutrophils and monocytes are influenced by the type of anticoagulation agent.

Authors:  Naser Abdallah Al Humam
Journal:  Vet World       Date:  2021-07-24

7.  The Impact of Anticoagulation Agent on the Composition and Phenotype of Blood Leukocytes in Dromedary Camels.

Authors:  Jamal Hussen; Turke Shawaf; Sameer M Alhojaily
Journal:  Vet Sci       Date:  2022-02-13

8.  The type of anticoagulant used for plasma collection affects in vitro Rhodococcus equi assays.

Authors:  Alejandra A Rivolta; Dana C Pittman; Amanda J Kappes; Robert K Stancil; Clark Kogan; Macarena G Sanz
Journal:  BMC Res Notes       Date:  2022-02-14

9.  Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood.

Authors:  Corinne J Smith; Nikki Ross; Ali Kamal; Kevin Y Kim; Elizabeth Kropf; Pascal Deschatelets; Cedric Francois; William J Quinn; Inderpal Singh; Anna Majowicz; Federico Mingozzi; Klaudia Kuranda
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786

10.  Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.

Authors:  Alessio Cortellini; Marco Tucci; Vincenzo Adamo; Luigia Stefania Stucci; Alessandro Russo; Enrica Teresa Tanda; Francesco Spagnolo; Francesca Rastelli; Renato Bisonni; Daniele Santini; Marco Russano; Cecilia Anesi; Raffaele Giusti; Marco Filetti; Paolo Marchetti; Andrea Botticelli; Alain Gelibter; Mario Alberto Occhipinti; Riccardo Marconcini; Maria Giuseppa Vitale; Linda Nicolardi; Rita Chiari; Claudia Bareggi; Olga Nigro; Alessandro Tuzi; Michele De Tursi; Nicola Petragnani; Laura Pala; Sergio Bracarda; Serena Macrini; Alessandro Inno; Federica Zoratto; Enzo Veltri; Barbara Di Cocco; Domenico Mallardo; Maria Grazia Vitale; David James Pinato; Giampiero Porzio; Corrado Ficorella; Paolo Antonio Ascierto
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.